KRAS and cancer: The prevalence of PIK3CA and KRAS mutations in normal tissues is consistent with the mathematically‐derived conclusion that “half or more of the somatic mutations in cancers of self‐renewing tissues originate prior to tumor initiation” [Tomasetti et al., 2017, 2013].